Incident CUD diagnosis in patients with overweight/obesity and a prior history of CUD comparison between propensity-score matched cohorts during 8-month follow-up time period

Population	Semaglutide cohort	Non-GLP1R agonist anti-obesity medications cohor	t	HR (95% CI)
Overall (n = 770/cohort)	10.39% (80)	17.27% (133)	├=-	0.59 (0.45–0.78)
Women (n = 486/cohort)	9.67% (47)	17.49% (85)	├ = ┤	0.55 (0.39–0.79)
Men (n = 244/cohort)	11.07% (27)	22.13% (54)	⊢= -	0.46 (0.29–0.73)
age <= 55 years (n = 383/cohort)	12.01% (46)	20.37% (78)		0.58 (0.41–0.84)
age > 55 years (n = 164/cohort)	<6.10% (<10)	15.85% (26)	├-	0.37 (0.18–0.77)
Black (n = 198/cohort)	9.60% (19)	14.65% (29)		0.65 (0.36–1.16)
White (n = 452/cohort)	9.29% (42)	15.04% (68)	├■ -	0.62 (0.42–0.91)
			0.10 0.20 0.40 0.80 2.0 4 Hazard Ratio (HR)	.0 8.00